<DOC>
	<DOCNO>NCT02527824</DOCNO>
	<brief_summary>This study conduct phase II study triple combination oxaliplatin , irinotecan , S-1 first-line chemotherapy patient advance biliary tract cancer .</brief_summary>
	<brief_title>Study Oxaliplatin , Irinotecan , S-1 Biliary Tract Cancer</brief_title>
	<detailed_description>It widely accept efficacy chemotherapy patient inoperable , advanced , metastatic biliary tract cancer well compare best supportive care . In general , gemcitabine base combination chemotherapy consider first line treatment patient advance biliary tract cancer , limitation inconvenience administration unsatisfactory efficacy . S-1 monotherapy combination oxaliplatin show objective response rate 21-35 % 24.5 % , respectively , irinotecan combine oxaliplatin show response rate 18-20.5 % patient advance metastatic biliary tract cancer . So investigator conduct phase I study three drug ( oxaliplatin , irinotecan , S-1 ) modification dosage schedule conduct phase II study recommend dose triple chemotherapy phase I study .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Pathologically confirm advanced , recurrent metastatic adenocarcinoma biliary tract system ( stage IV primary tumor , regional node , metastasis ( TNM ) stag system ) Eastern Cooperative Oncology Group ( ECOG ) performance status 02 More 3 month expect life span Measurable lesion RECIST criterion version 1.1 Palliative chemotherapy naive Adequate organ function Participants must sign informed consent indicate aware investigational nature study keep policy hospital Any prior 2 year concurrent malignancy nonmelanoma skin cancer , situ cancer uterine cervix , papillary follicular thyroid cancer . Participants receive radiation therapy target lesion 4 week study enrollment Participants receive major surgery 4 week study enrollment Participants active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , myocardial infarction precede 12 month , pregnancy , breast feeding Participants central nervous system ( CNS ) metastases Participants peripheral sensory neuropathy impair functional activity Participants gastrointestinal obstruction bleed induce malabsorption oral chemotherapeutic agent .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>biliary tract neoplasm</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>S-1</keyword>
</DOC>